Izastobart
- Generic Name
- Izastobart
A Study of Safety and Drug Levels of HIB210 in Healthy Volunteers
- First Posted Date
- 2023-07-03
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- HI-Bio, A Biogen Company
- Target Recruit Count
- 30
- Registration Number
- NCT05928585
- Locations
- 🇺🇸
HI-Bio Investigational Site, Hialeah, Florida, United States
Expanded Access Protocol for Subjects With Relapsed or Refractory Advanced Solid Tumors Receiving TJ210001
- Conditions
- Solid Tumor Metastatic Cancer Advanced Cancer
- First Posted Date
- 2022-08-23
- Last Posted Date
- 2022-10-18
- Lead Sponsor
- I-Mab Biopharma US Limited
- Registration Number
- NCT05511350
Study of TJ210001 Administered in Subjects With Relapsed or Refractory Advanced Solid Tumors
- First Posted Date
- 2020-12-22
- Last Posted Date
- 2022-12-12
- Lead Sponsor
- I-Mab Biopharma US Limited
- Target Recruit Count
- 16
- Registration Number
- NCT04678921
- Locations
- 🇺🇸
Horizon Oncology Center, Lafayette, Indiana, United States
🇺🇸University of Colorado Hospital - Anschutz Cancer Pavilion, Aurora, Colorado, United States
🇺🇸Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath